Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current. 

Category
Displaying 1 - 50 of 430
Date Sort ascending
CL_2018-42.pdf

INFORMATION ONLY
Donation Number Label Change

Customer Letter 2018-42 (PDF)

CL_2018-41.pdf

INFORMATION ONLY
Now Posted - NAC Endorsement of the ICTMG Platelet Guidelines

Customer Letter 2018-41 (PDF)

CL_2018-40.pdf

INFORMATION ONLY
Revision - Availability of Immune Globulin Products for 2018-2019

Customer Letter 2018-40 (PDF)

CL_2018-39.pdf

ACTION REQUIRED
HLA/HPA Testing Process

Customer Letter 2018-39 (PDF)

CL_2018-38.pdf

INFORMATION ONLY
Revision to the IgA/Anti-IgA Patient Request Form

Customer Letter 2018-38 (PDF)

CL_2018-37.pdf

ACTION REQUIRED
HLA/HPA Request Process Update 

Customer Letter 2018-37 (PDF)

 

CL_2018-36.pdf

INFORMATION ONLY
RHCE and Extended Blood Group Genotyping for Alberta Hospitals 

Customer Letter 2018-36 (PDF)

CL_2018-35.pdf

ACTION REQUIRED
Subcutaneous Immune Globulin Transition Update 

Customer Letter 2018-35 (PDF)

CL_2018-34.pdf

ACTION REQUIRED
Requesting Eloctate and Alprolix for Eligible Patients 

Customer Letter 2018-34 (PDF)

English attachment : F801219 - sample
CL_2018-33.pdf

INFORMATION ONLY
Now Posted – Recommendations for the Use of Irradiated Blood Components in Canada

Customer Letter 2018-33 (PDF)

CL2018-32.pdf

INFORMATION ONLY
Plasma Protein Products Transition Newsletter – August 2018

Customer Letter 2018-32 (PDF)  |  Plasma Protein Products Transition Newsletter – August 2018

CL_2018-31.pdf

INFORMATION ONLY
Nuwiq 3000 IU and 4000 IU Vial Sizes Available for Distribution

Customer Letter 2018-31 (PDF)  |  Octapharma - Nuwiq 3000 IU and 4000 IU Vial Sizes Available for Distribution

CL_2018-30.pdf

INFORMATION ONLY
Release of Revised Circulars of Information for Red Blood Cells, Platelets, and Plasma

Customer Letter 2018-30 (PDF)

CL_2018-29.pdf

INFORMATION ONLY
Canadian Babesiosis Study

Customer Letter 2018-29 (PDF)

CL_2018-28.pdf

INFORMATION ONLY 
Planned Changes to the Hospital Feedback Process 

Customer Letter 2018-28 (PDF)

CL_2018-27.pdf

INFORMATION ONLY 
Plasma Protein Products Transition Newsletter – June 2018

Customer Letter 2018-27(PDF) | Plasma Protein Products Transition Newsletter – June 2018

CL_2018-25.pdf

INFORMATION ONLY
Privigen® 20g (10%) Lot 4357600032 Distribution Hold Cancellation

Customer Letter 2018-25 (PDF) | Privigen® 20g (10%) Lot 4357600032 Distribution Hold Cancellation

CL_2018-26.pdf

INFORMATION ONLY 
Introduction of Fresenius Kabi Platelets, Pooled Storage Container 

Customer Letter 2018-26 (PDF)

CL_2018-24.pdf

INFORMATION ONLY 
New Packaging for CSL Behring Products

Customer Letter 2018-24 (PDF) | New Packaging for Berinert®, Beriplex® PN, Corifact®, Humate-P® and RiaSTAP® (PDF)

CL_2018-23_PPP_Trend_Reports.pdf

INFORMATION ONLY
Launch of Hospital Plasma Protein Product Disposition Trend Graphs

Customer Letter 2018-23 (PDF)

CL_2018-22.pdf

INFORMATION ONLY
Canadian Blood Services – Diagnostic Services Revised Web Pages

Customer Letter 2018-22 (PDF)

CL_2018-21.pdf

INFORMATION ONLY
Qualification Information - New Insulated Shipping Containers for Hospital Deliveries

Attachment_1_CL_2018-21.pdf | Attachment_2_CL_2018-21.pdf
CL_2018-20.pdf

INFORMATION ONLY
Plasma Protein Products Transition Newsletter – May 2018

PPP_Transition_Newsletter_May_2018.pdf
CL_2018-19.pdf

INFORMATION ONLY
New Factor Products now available from Canadian Blood Services

Novo-Nordisk-HC-approves-Rebinyn.pdf | Shire-Adynovate-available-CBS.pdf
CL_2018-18.pdf

INFORMATION ONLY 
Cuvitru and Gammagard Liquid now available from Canadian Blood Services

Shire_Customer_Letter_-_Cuvitru_20_will_soon_be_available_through_Canadian_Blood_Services.pdf
CL_2018-17.pdf

INFORMATION ONLY
Plasma Protein Products Manufacturer Updates
(CSL Behring, Octapharma and Grifols)

CSL_Behring_Notification_of_Change_to_Lot_Numbering_Structure.pdf | Octapharma_Octaplex_now_Available_with_3_Year_Shelf_Life.pdf | Grifols_Important_Changes_in_Recomended_Dosage_Instructions_for_GamaSTAN_SD.pdf | Grifols_Change_in_Appearance_of_Pre-filled_Syringes_for_HyperHep_B_SD.pdf
CL_2018-16.pdf

INFORMATION ONLY 
Follow-up to Production Announcement – Transfer of Regina Production Activities to Calgary

Customer Letter 2018-16 (PDF)

CL_2018-15.pdf

INFORMATION ONLY
Availability of Immune Globulin Products for 2018-2019

Customer Letter 2018-15 (PDF)

CL_2018-14.pdf

INFORMATION ONLY
Plasma Protein Products Transition Newsletter – March 2018

Customer Letter 2018-14 (PDF)

PPP_Transition_March_2018_Newsletter.pdf
CL_2018-13.pdf

INFORMATION ONLY
Introduction of Rare Blood Program

Customer Letter 2018-13 (PDF)

CL_2018-12.pdf

INFORMATION ONLY
Further Information; Health Canada Approval, Changes to Red Blood Cell Extended Antigen Printing on the End Label

Customer Letter 2018-12 (PDF)

CL_2018-11.pdf

INFORMATION ONLY
Implementation Update: Increase in Collections of ACD-A Apheresis Fresh Frozen Plasma and New ISBT Component Codes

Customer Letter 2018-11 (PDF)

CL_2018-_10.pdf

INFORMATION ONLY 
Plasma Protein Products Transition Newsletter – February 2018

Customer Letter 2018-10 (PDF)

Feb_2018_Newsletter_EN.pdf
CL_2018-09.pdf

INFORMATION ONLY
Introduction of coloured dots on some of our blood components

Customer Letter 2018-09 (PDF)

CL_2018-08.pdf

INFORMATION ONLY
Grifols’ Albumin (Human) 5% and 25% – Low Aluminum

Customer Letter 2018-08 (PDF) 

Grifols_Customer_Letter_2018-02-15.pdf
CL_2018-07.pdf

INFORMATION ONLY
OBIZUR now available from Canadian Blood Services

Customer Letter 2018-07 (PDF)

Shire-Healthcare_Professionals_Letter.pdf
CL_2018-06.pdf

INFORMATION ONLY
Release of Companion Components Associated with a Confirmed Negative Bacterial Screening Test

Customer Letter 2018-06 (PDF)

CL_2018-05.pdf

INFORMATION ONLY
Factor XI Concentrate Inventory Alert

Customer Letter 2018-05 (PDF)

CL_2018-04.pdf

INFORMATION ONLY
Plasma Protein Products Transition Newsletter – January 2018

Customer Letter 2018-04 (PDF)

CL_2018-03.pdf

INFORMATION ONLY
Release of Revised Circular of Information for Plasma Components

Customer Letter 2018-03 (PDF)

CL_2018-02.pdf

INFORMATION ONLY
Notification of Change of Site for IgA Program

Customer Letter 2018-02 (PDF)

IgA_anti-IgA_Patient-request-form.pdf
CL_2018-01.pdf

INFORMATION ONLY
Revisions to the Special Request Order Form

Customer Letter 2018-01 (PDF)

CL_2017-48.pdf

ACTION REQUIRED
Increase in Collection of ACD-A Apheresis Fresh Frozen Plasma and New ISBT Component Codes

 

CL_2017-47.pdf

INFORMATION ONLY
2017 Holiday Message and Inventory Update

 

CL_2017-46.pdf

INFORMATION ONLY
Plasma Protein Products Request for Proposal Results-Update

 

FAQ-Fractionation_Services_and_Recombinant_Plasma_Protein_Products_Product_Supply_and_Transitioning.pdf | Plasma_Protein_Products_Transition_December_2017_Newsletter.pdf
CL_2017-45.pdf

INFORMATION ONLY
Important Information Regarding Panzyga Availability

 

CL_2017-44.pdf

INFORMATION ONLY 
Updates to CSL Behring’s Products

 

Alburex_5_and_Alburex_25_with_Tamper_Evident_Packaging_-_November_17_2017.pdf | Hizentra_Introduction_of_Pre-filled_Syringe_PFS_1g_and_2g_-_November_24_2017.pdf | Hizentra_Pre-filled_Syringe_Specifications_Sheet.pdf
CL_2017-43.pdf

INFORMATION ONLY
Plasma Protein Products Updates

 

Bayer_Customer_Letter_-_Re-Introduction_of_the_5_mL_Syringe_for_all_Potencies_of_Kovaltry.pdf | Octapharma_Customer_Letter_-_Panzyga_is_now_approved_for_Guillain-Barre_Syndrome_GBS.pdf
CL_2017-42.pdf

INFORMATION ONLY
Plasma Protein Products Request for Proposal Results

 

CL_2017-41.pdf

INFORMATION ONLY
The Transfer of Diagnostic Services From Regina to Vancouver

 

Book your donation